Xbrane Biopharma AB (publ) (STO:XBRANE)

Sweden · Delayed Price · Currency is SEK

5.95

+0.29 (5.11%)

Mar 20, 2026, 5:29 PM CET

Revenue by Segment

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Biosimilar Development	152.35M	198.72M	238.73M	57.62M	10.71M
Biosimilar Development Growth	-23.33%	-16.76%	314.33%	438.03%	-
Total	152.35M	198.72M	238.73M	57.62M	10.71M
Total Growth	-23.33%	-16.76%	314.33%	438.03%	-

Revenue by Geography

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Germany	67.50M	66.50M	209.90M	-	-
Germany Growth	1.50%	-68.32%	-	-	-
Others	600.00K	-	-	-	-
India	84.30M	54.10M	-	-	-
India Growth	55.82%	-	-	-	-
North America	-	77.00M	28.70M	-	-
North America Growth	-	168.29%	-	-	-
Total	152.40M	197.60M	238.60M	-	-
Total Growth	-22.87%	-17.18%	-	-	-

Source: S&P Global Market Intelligence.